A young girl developed extensive striae while on Depo Provera injections. She had gained some weight during the treatment. Endocrinal investigations were negative. The development of striae was attributed to her weight gain.
on the combined oral contraceptive pill or try any of the other non-hormonal methods.
On her next visit the following month, she was continuing to gain weight. It is not definite that she followed any dietary advice. She did not feel that her weight gain had anything to do with her eating habits. All the information, including Medline search results, were discussed with her at each stage. At this point, she was referred to the consultant endocrinologist to exclude endocrine problems. She was found to have a normal cortisol level and had a normal overnight dexamethazone suppression test. The consultant's view was that her overall weight gain of 5-6 Kg at a height of 154 cm was probably sufficient to cause the striae. This was explained to her, and the importance of controlling her weight was stressed.
On her subsequent visits, she continued to gain weight. Dietary advice was not followed. Her striae became less florid as the time progressed, but still continued to cause her distress. A search through Pharmacia and Upjohn, the manufacturer, showed very few reported cases of striae developing following Depo Provera injection. The most recent search of their world-wide spontaneous adverse events database (completed 28 th April 98) shows that they have received 28 reports of striae in women on Depo Provera since market introduction of the product in 1960. Where known, onset of symptoms ranged from 2 days to 4 years following the first Depo Provera injection. A full recovery was reported in only one case. In this case, the striae appeared 6 months after starting the Depo Provera and the event resolved spontaneously without treatment about 4 months later while the patient continued Depo Provera. In most cases the outcome of the events was not reported or was unknown.
The British Journal of Family
In the reports received by the company, no opinions were provided as to the cause of the striae. In 10 reports, however, weight gain and/or a history of weight problems were noted. One of the cases from UK was published where authors suggested that the striae might have been the result of an idiosyncratic reaction to Depo Provera. 1 No other published references were found.
The data from Pharmacia and Upjohn are from a spontaneous medical event reporting system, which consists of a world-wide database of unsolicited reports. As with all spontaneous reporting systems, there is not necessarily a causal relationship between the use of a drug and the occurrence of an event. The numbers of events collected through this system must be interpreted as reporting rates and not incidence rates. 2
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